Indeed, that anxiety has put pressure on the shares of both Moderna and Pfizer. Its stock soared when it emerged as a Covid-shot frontrunner, but it’s facing increasing skepticism from investors who say its next products are years away from the market - and that in the meantime, a deep sales slide could be in the offing for Covid vaccines. Moderna has reached an important moment in its brief history. “They’re trying to figure out how to play mine.” “I don’t intend to beat them at their game,” he said. But Moderna’s superior technology and RNA know-how will allow it to pull ahead as the market matures, Hoge predicted. Moderna was started in 2010 and has just one product on the market, its vaccine.
Additionally, its partner, BioNTech SE, had been working on mRNA for years. The pharmaceutical giant, founded in 1849, has developed countless household-name therapies. Hoge said Pfizer’s experience with fast clinical trials and mass production allowed it to excel in the short run. “We’ve been doing this for a few years, we’re the creators of this space.” vaccines, Moderna President Stephen Hoge said in an interview on Friday. “We’re not dabbling” in mRNA, the technology that is the backbone of both the leading U.S. executives say their company’s long experience with messenger RNA technology give it a more enduring advantage. has been first across the finish line in nearly every leg of the Covid-19 vaccine race, but Moderna Inc.
0 kommentar(er)
